home / stock / addxf / addxf short
Short Information | Addex Pharms Ltd Ord (OTCMKTS:ADDXF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 30,134 |
Total Actual Volume | 30,134 |
Short Trends | |
---|---|
Cover Days | 0 |
Short Days | 13 |
No Change Days | 0 |
Averages | |
---|---|
Average Short Volume | 1,507 |
Average Short Percentage | 65.00% |
Is there a ADDXF Short Squeeze or Breakout about to happen?
See the ADDXF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
09-26-2019 | $1.91 | $1.91 | $1.91 | $1.91 | 7,500 | 7,500 | 100% |
06-05-2019 | $1.54 | $1.54 | $1.54 | $1.54 | 2,000 | 2,000 | 100% |
05-21-2019 | $1.70 | $1.70 | $1.70 | $1.70 | 5,000 | 5,000 | 100% |
11-05-2018 | $N/A | $2.64 | $N/A | $N/A | 4 | 4 | 100% |
10-12-2018 | $N/A | $2.64 | $N/A | $N/A | 15 | 15 | 100% |
05-02-2018 | $3.30 | $3.30 | $3.30 | $3.30 | 666 | 666 | 100% |
04-12-2018 | $3.3031 | $3.3031 | $3.3031 | $3.3031 | 1,422 | 1,422 | 100% |
04-09-2018 | $3.2193 | $3.2193 | $3.2193 | $3.2193 | 466 | 466 | 100% |
03-23-2018 | $2.95 | $2.95 | $2.95 | $2.95 | 2,124 | 2,124 | 100% |
01-26-2018 | $N/A | $3.41 | $N/A | $N/A | 25 | 25 | 100% |
01-17-2018 | $3.41 | $3.41 | $3.41 | $3.41 | 5,812 | 5,812 | 100% |
01-10-2018 | $3.44 | $3.44 | $3.44 | $3.44 | 100 | 100 | 100% |
01-04-2018 | $4.05 | $4.05 | $4.05 | $4.05 | 5,000 | 5,000 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Addex Pharms Ltd Ord Company Name:
ADDXF Stock Symbol:
OTCMKTS Market:
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, t...
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April ...
Top-line data from ADX71149 Phase 2 epilepsy study expected by mid-May 2024 Launched Neurosterix with Perceptive Advisors, raising USD 63 million in Series A to accelerate development of preclinical portfolio Received CHF 5 million upfront and 20% equity in Neurosterix, providing ...